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Summary
Context As a result of the introduction of treatment with gluco-
corticoids and mineralocorticoids, now 60 years ago, congenital
adrenal hyperplasia has become a lifelong chronic disease. Whether
long-term treatment of the disease leads to long-term side effects
remains unknown. In this respect, especially cardiovascular risk
seems to be important.
Evidence synthesis We reviewed the reported prevalence of
conventional cardiovascular risk factors, i.e. obesity, insulin resis-
tance, high blood pressure and dyslipidaemia in patients with con-
genital adrenal hyperplasia. Overall, the studies suggest a tendency
towards an increased body mass index and fat mass, the presence of
insulin resistance and hypertension, although data are relatively
scarce and obtained in heterogeneous populations.
Conclusions Our findings suggest that adult CAH patients tend
to have a cluster of metabolic risk factors, which are consistent with
the metabolic syndrome. This notion may have consequences for
the care for this group of patients.
(Received 28 April 2009; returned for revision 27 May 2009; finally
revised 22 June 2009; accepted 22 July 2009)
Introduction
Congenital adrenal hyperplasia (CAH) is a disorder of adrenal ste-
roidogenesis. Treatment with glucocorticoids and, if necessary,
mineralocorticoids prevents adrenal crises and suppresses abnor-
mal secretion of adrenal androgens. As a result of the introduction
of treatment with glucocorticoids and mineralocorticoids, now
60 years ago, nearly all CAH patients currently reach adulthood.
This renders it possible to unfold the clinical spectrum of CAH as a
lifelong chronic disease, with the oldest salt-wasting patients now
being in their 60s, and long-term consequences of therapy becom-
ing increasingly important. Patients with CAH are at risk of devel-
oping signs and symptoms of iatrogenic Cushing’s syndrome1,2 as
the therapeutic range of treatment with glucocorticoids is narrow
and supraphysiological doses of glucocorticoids are used to sup-
press hyperandrogenism. As hypercortisolism is associated with
cardiovascular morbidity,3 it is suggested that patients with CAH
may show an adverse cardiovascular risk profile.4 Furthermore,
other factors such as obesity and alterations in the leptin axis may
contribute to the development of an unfavourable cardiovascular
risk profile in CAH patients. In this review, we discuss cardiovascu-
lar risk factors in paediatric and adult CAH patients. Data reviewed
in this paper are from patients suffering from CAH because of
21-hydroxylase deficiency unless stated otherwise.
Overview of CAH
In 95% of cases, CAH is caused by 21-hydroxylase deficiency.2
Deficiency of 21-hydroxylase results in impaired adrenal synthesis
of cortisol and often also of aldosterone, causing increased secre-
tion of ACTH by the pituitary gland, adrenal hyperplasia and
excessive production of adrenal androgens.
The symptoms of CAH depend on the degree of enzyme defi-
ciency. Patients with the classic salt wasting (SW) type of CAH have
no residual enzyme activity resulting in disturbed cortisol and
aldosterone production typically leading to an Addisonian crisis
7–14 days after birth and prenatal virilization of the external geni-
talia in females. Patients with the classic simple virilizing (SV) type
of CAH have a residual enzyme activity of 1–2% and are considered
to have sufficient aldosterone production to prevent severe salt
wasting. The simple virilizing form results in prenatal virilization
in females and postnatal androgen excess in both sexes, when left
untreated, leading to precocious pseudopuberty at a young age.
The two classic forms of CAH have an incidence of approximately
1 in 15 000 live births worldwide.5 The nonclassic or late onset
form of CAH with a residual enzyme activity of 30–50% has a prev-
alence of 0Æ1% in the general white population,6 a higher frequency
being reported in Eastern European Jews (3–4%), and in Hispanics
and Yugoslavs (1–2%).6 Female patients may be asymptomatic or
are characterized by signs and symptoms of hyperandrogenism
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such as abnormalities of the menstrual cycle, acne, hirsutism and
subfertility. Therefore, signs and symptoms in women with the late
onset form of congenital adrenal hyperplasia are comparable with
those seen in women with polycystic ovary syndrome.2,7 Male
patients are usually asymptomatic but occasionally, they present
with subfertility caused by hypogonadotrophic hypogonadism
because of suppression of gonadotrophins by elevated adrenal
androgens.
Risk factors for atherosclerotic vascular disease
Atherosclerotic vascular disease is caused by a complex process, to
which several risk factors contribute.8 Traditional risk factors
include age, male gender, familial predisposition, obesity, diabetes
mellitus, dyslipidaemia, hypertension, smoking and a sedentary
lifestyle. In addition, several new nontraditional risk factors have
been identified.8 In the following part, some of these risk factors in
CAH patients will be discussed in more detail.
Obesity
An increased fat mass and the presence of abdominal obesity are
important factors in the development of cardiovascular disease.
Many studies have investigated body mass index (BMI) in CAH
patients and most,9–18 but not all,19,20 of them report an elevated
BMI. Studies regarding body composition in patients with CAH
are summarized in Table 1. Most studies used dual X-ray absorpti-
ometry (DXA) scans to evaluate body composition, and one study
used skinfold measurements.
In a cross-sectional study, Stikkelbroeck et al.9 found an ele-
vated BMI in young male and female adult CAH patients
(n = 30, aged 17–25 years) compared with healthy controls.
Increase in BMI was caused by an increase in fat mass. Fat mass
adjusted for height and relative fat mass (i.e. fat mass divided by
total body mass) was significantly higher in both males and
females. Body fat distribution (measured by DXA) did not differ
between patients and controls. Falhammar et al.10 found a higher
BMI in female CAH patients aged 30 years or older (n = 34)
compared with controls. The elevated BMI in female CAH
patients was not accompanied by elevation of total fat mass as
found by Stikkelbroeck et al.9 Falhammar et al.10 did not find dif-
ferences either in BMI or in body composition in female CAH
patients younger than 30 years of age (n = 27) compared with
controls. Bachelot et al.11 reported a high BMI in adult male and
female CAH patients (n = 45), but BMI in CAH patients was not
compared with control subjects. BMI did not differ between the
various clinical forms of CAH. BMI also showed no correlation
with duration of treatment, dosage of hydrocortisone and
17alpha-hydroxyprogesterone (17-OHP) levels.
In a study by Hagenfeldt et al.12 a significantly higher weight,
BMI and absolute amount of body fat were found, but the fat/lean
body mass ratio was not different between adult female CAH
patients and age-matched healthy reference subjects. Cameron
et al.19 and Christiansen et al.21 described an increased fat mass in
male but not in female CAH patients. However, because different
parameters were used in the different studies, i.e. relative fat mass
and fat mass adjusted for height by Stikkelbroeck et al.,9 fat/lean
ratio by Cameron et al.19 and fat mass percentage by Christiansen
et al.,21 it is difficult to compare these results.
Two studies have described BMI and body composition in chil-
dren with CAH. Cornean et al.13 reported an increased BMI in 21-
hydroxylase-deficient children in a retrospective study. ‘Adiposity
rebound’, defined as the age at which the decrease in BMI reverses,
was assessed in a subset of 13 patients (nine boys, four girls) in
which longitudinal data were available from birth. ‘Adiposity
rebound’ took place at a mean age of 1Æ74 years in the patients
compared with 5Æ5 years for controls from the normal UK popula-
tion. Early ‘adiposity rebound’ is of importance as it increases the
risk for the development of obesity in adolescence.22 The increment
in BMI was attributed to an increase in fat mass, skinfold thickness
increasing significantly between 2Æ5 and 5Æ5 years. A limitation of
this study is that data were collected retrospectively and that skin-
fold measurements to determine body composition were used.
Vo¨lkl et al.14 evaluated BMI in children in a retrospective cross-
sectional study of 89 CAH patients (aged 0Æ2–17Æ9 years). BMI SDS
of the whole group was significantly elevated. In addition, a signi-
ficantly higher frequency of obesity, defined as BMI SDS >2Æ0, was
observed. Glucocorticoid dosage was positively correlated with
BMI SDS, although there was no significant difference in gluco-
corticoid and mineralocorticoid dosage between patients with a
BMI SDS of >2Æ0 and <2Æ0.
In summary, CAH is associated with an increase in BMI and an
increase in body fat in both adult and paediatric
patients.9,10,12,13,19,21 Further investigations are needed to define
the time of onset of obesity especially in children with CAH. The
cause of the excessive increase in body weight remains unclear, but
several factors may contribute. It is suspected that obesity in CAH
patients is related to glucocorticoid treatment. Obesity is reported
in patients treated with both ‘physiological’ and supraphysiological
doses of glucocorticoids. Furthermore, adrenomedullary dysfunc-
tion with decreased secretion of adrenaline may play a role in the
development of obesity.23 Catecholamines, such as adrenaline, con-
tribute to lipolysis and inhibit insulin secretion, thereby preventing
an increase in fat mass.24 The decreased secretion of adrenaline in
CAH is the result of prenatal adrenomedullary maldevelopment,23
caused by low intra-adrenal levels of glucocorticoids.25 Hypogona-
dism in men and hyperandrogenism in women are also associated
with the development of obesity in CAH patients.26 Another possi-
ble explanation for the presence of obesity in CAH patients is an
altered leptin axis.17
Leptin is known to play a role in the regulation of body weight,
with an increased leptin level suppressing appetite. The fact that
most obese persons exhibit high leptin concentrations is often
explained by the hypothesis that obesity is a state of leptin ‘resis-
tance’.27 Changes in the leptin axis, for example a decrease in leptin
receptor levels, may play a role in the development of obesity.28–31
Both glucocorticoids and insulin increase leptin concentra-
tions.32,33 In contrast, androgens are known to decrease leptin con-
centrations.34,35 Therefore, in CAH patients, an altered leptin axis
may play a role in the development of obesity.
A decrease in soluble leptin receptor (sOB-R) serum levels has
been described in CAH patients (aged 5Æ6–19Æ6 years, n = 51).17
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This observation suggests that also membrane leptin receptors are
decreased leading to a state of ‘leptin resistance’. In this study,
sOB-R:leptin ratios and serum leptin levels were significantly corre-
lated with insulin levels and insulin sensitivity. Serum leptin levels
were not different in CAH patients compared with matched con-
trols. In other studies, serum leptin levels have been described to be
elevated36 or normal37 in CAH patients. Leptin levels are known to
be correlated with fat mass. Two studies showed a positive correla-
tion between BMI and serum leptin levels.17,37 A positive correla-
tion between the percentage of body fat and leptin levels was noted
by Saygili et al.37
Dyslipidaemia
Only five studies have reported on lipid profiles in CAH
patients.10,11,38–40 Bayraktar et al.38 studied untreated adult female
nonclassic CAH patients (n = 50, aged 22 ± 2Æ91 years) and found
that lipid profiles were not different from controls (i.e. total choles-
terol, 4Æ6 ± 0Æ83 vs. 4Æ7 ± 0Æ77 mmol/l; HDL-cholesterol,
1Æ50 ± 0Æ28 vs. 1Æ55 ± 0Æ26 mmol/l; LDL-cholesterol, 2Æ56 ± 0Æ56
vs. 2Æ58 ± 0Æ58 mmol/l; and triglycerides, 1Æ14 ± 0Æ13 vs.
1Æ01 ± 0Æ12 mmol/l). Sartorato et al.39 found similar results in
male and female adult patients with the classic form of CAH caused
by 21-hydroxylase deficiency, all treated with glucocorticoids
(n = 19, aged 28 ± 3Æ5 years). Lipid profiles were not significantly
different compared with healthy controls (total cholesterol,
168 ± 49 vs. 189 ± 36 mg/dl; HDL-cholesterol, 65 ± 15 vs.
61 ± 32 mg/dl; and triglycerides, 83 ± 37 vs. 84 ± 56 mg/dl).
Falhammar et al.10 evaluated serum lipids in treated adult females
with classic and nonclassic CAH caused by 21-hydroxylase defi-
ciency (n = 61). Patients were divided into two groups: patients
younger than 30 years and patients 30 years or older. All patients
received treatment with prednisolone or hydrocortisone. Most
patients (50 of 61) also received fludrocortisone. Total cholesterol,
HDL-cholesterol, LDL-cholesterol, HDL to LDL ratio and triglyce-
rides did not differ between younger patients and controls. Patients
of 30 years of age or older had higher HDL to LDL ratios
(P = 0Æ03) and a tendency towards higher HDL-cholesterol
(P = 0Æ074) compared with healthy controls. This change in lipid
profile is considered to be protective for cardiovascular disease. Fal-
hammar et al.10 did not show any unfavourable changes in the lipid
profile of adult female CAH patients. Bachelot et al.11 found nor-
mal total cholesterol, triglycerides and LDL-cholesterol levels in
adult patients with classic CAH, both with a BMI < 25 (n = 24)
and with a BMI > 25 (n = 21).
Only one study evaluated lipid profiles in children with CAH.
Botero et al.40 determined serum lipid profiles in 14 prepubertal
children with CAH caused by 21-hydroxylase deficiency (four boys
and 10 girls; aged 13 months–10 years) and in 14 healthy prepu-
bertal children (eight boys and six girls; aged 21 months–9 years).
All CAH patients were on glucocorticoid treatment with predni-
sone (dosage equivalent to 10–20 mg/m2/day hydrocortisone). The
study provided no information about the type of CAH and no
matched control group was used. A statistically significant larger
percentage of patients in the CAH group had serum triglycerides
above 1Æ0 mmol/l compared with the control group (64Æ3% vs.
14Æ3%). Mean serum levels of triglycerides were also significantly
elevated compared with the control group (1Æ32 ± 0Æ15 vs.
0Æ75 ± 0Æ07 mmol/l; P = 0Æ04). These findings were attributed to
the use of glucocorticoids, especially prednisone. Furthermore,
insulin resistance may also have contributed to the elevated levels
of triglycerides. Mean serum levels of total cholesterol, LDL-choles-
terol and HDL-cholesterol were not significantly different com-
pared with controls.
In summary, studies evaluating the lipid profile in adult CAH
patients10,11,38,39 did not show unfavourable changes. Therefore, an
altered lipid profile does not seem to be an important cardiovascu-
lar risk factor in adult CAH patients. Because obesity and insulin
resistance (see further), both observed in CAH patients, are known
to be associated with dyslipidaemia41, it is surprising that lipid pro-
files in CAH patients are normal. A possible explanation for this
finding is that lipid profiles were mainly evaluated in younger CAH
patients. Evaluation of dyslipidaemia in older CAH patients,
especially those older than 50 years of age, is needed.
Hypertension
Seven studies have evaluated blood pressure in CAH
patients10,39,42–46 as summarized in Table 2. Two studies10,39 have
evaluated blood pressure only in adult CAH patients, four stud-
ies42–45 in both paediatric and young adult patients and one study46
reports on blood pressure in paediatric CAH patients only.
Falhammar et al.10 found supine and upright blood pressure
values mostly within the normal range, both in female CAH
patients younger than 30 years (n = 27) and 30 years or older
(n = 34). No differences in supine and upright blood pressures
were observed in female CAH patients and healthy controls. Three
CAH patients older than 30 years received antihypertensive ther-
apy, whereas controls did not receive antihypertensive medication.
Defining hypertension as a supine blood pressure >140/90 mmHg,
three CAH patients and four controls older than 30 years showed
hypertension. Sartorato et al.39 found blood pressure values within
the normal range in both male and female classic CAH patients
receiving glucocorticoid replacement therapy with hydrocortisone
or dexamethasone. In both male (n = 9) and female (n = 10) CAH
patients, systolic and diastolic blood pressures did not differ from
healthy controls.
De Silva et al.42 performed 24-h ambulatory blood pressure
monitoring in 11 treated CAH patients (M:F = 4:7) with a mean
age of 14Æ5 years. Nine patients were 21-hydroxylase deficient (five
salt losers), one patient had 11b-hydroxylase deficiency and one
had lipoid adrenal hyperplasia. None of the patients had hyperten-
sion defined as a mean systolic and diastolic blood pressure >95th
percentile. However, five patients had a high mean blood pressure
(90th percentile) with elevated mean systolic and diastolic pres-
sures during the awake period. Limitations of this study are the
small sample size of the study population and the heterogeneity of
patients, with inclusion of both children and adults, two of them
not being 21-hydroxylase deficient. In addition, two different blood
pressure references were used: 24-h ambulatory blood pressure spe-
cific references and office blood pressure references. When using
specific ambulatory reference data, one patient showed both
140 C. F. Mooij et al.
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T
ab
le
2.
Su
m
m
ar
y
o
f
st
u
d
ie
s
ad
d
re
ss
in
g
b
lo
o
d
p
re
ss
u
re
in
co
n
ge
n
it
al
ad
re
n
al
h
yp
er
p
la
si
a
St
u
d
y
(r
ef
.)
St
u
d
y
p
o
p
u
la
ti
o
n
(n
)
G
en
d
er
A
ge
(y
ea
rs
),
m
ea
n
±
SD
T
h
er
ap
y
C
A
H
gr
o
u
p
M
et
h
o
d
s
B
lo
o
d
p
re
ss
u
re
(m
m
H
g)
(±
SD
)
F
al
h
am
m
ar
et
al
.1
0
Sa
lt
-w
as
ti
n
g
(2
7)
Si
m
p
le
vi
ri
li
zi
n
g
(2
8)
N
o
n
cl
as
si
c
(6
)
A
ge
-m
at
ch
ed
co
n
tr
o
ls
(6
1)
61
$
61
$
18
–
63
(r
an
ge
)
18
–
63
(r
an
ge
)
A
ll
p
at
ie
n
ts
:g
lu
co
co
rt
ic
o
id
s
(±
50
%
p
re
d
n
is
o
lo
n
e,
±
33
%
h
yd
ro
co
rt
is
o
n
e,
o
th
er
s
co
rt
is
o
n
e
ac
et
at
e,
d
ex
am
et
h
as
o
n
e
o
r
co
m
b
in
at
io
n
82
%
fl
u
d
ro
co
rt
is
o
n
e
B
P
w
as
re
gi
st
er
ed
su
p
in
e
an
d
st
an
d
in
g
$<
30
ye
ar
s:
11
0/
71
(s
u
p
in
e)
$<
30
ye
ar
s:
12
0/
75
(u
p
ri
gh
t)
$>
30
ye
ar
s:
11
0/
75
(s
u
p
in
e)
$>
30
ye
ar
s:
11
5/
79
(u
p
ri
gh
t)
Sa
rt
o
ra
to
et
al
.3
9
C
la
ss
ic
21
-O
H
d
efi
ci
en
cy
(1
9)
•
Sa
lt
-w
as
ti
n
g
(1
2)
•
Si
m
p
le
vi
ri
li
zi
n
g
(7
)
C
o
n
tr
o
ls
(1
9)
10
$;
9#
10
$;
9#
28
±
3Æ
5
A
ll
p
at
ie
n
ts
:g
lu
co
co
rt
ic
o
id
re
p
la
ce
m
en
t
w
it
h
h
yd
ro
co
rt
is
o
n
e
o
r
d
ex
am
et
h
as
o
n
e
12
p
at
ie
n
ts
m
in
er
al
o
co
rt
ic
o
id
th
er
ap
y
A
ve
ra
ge
o
f
th
re
e
B
P
m
ea
su
re
m
en
ts
w
it
h
a
sp
h
yg
m
o
m
an
o
m
et
er
o
n
se
p
ar
at
e
o
cc
as
io
n
s
#
:S
B
P
12
3Æ
3
±
13
Æ2
#
:D
B
P
83
Æ3
±
8Æ
7
$:
SB
P
12
6Æ
5
±
7Æ
5
$:
D
B
P
83
Æ9
±
4Æ
9
D
e
Si
lv
a
et
al
.4
2
C
la
ss
ic
21
-O
H
d
efi
ci
en
cy
(9
)
•
Sa
lt
-w
as
ti
n
g
(5
)
11
b-
h
yd
ro
xy
la
se
d
efi
ci
en
cy
(1
)
L
ip
o
id
ad
re
n
al
h
yp
er
p
la
si
a
(1
)
7
$;
4#
14
Æ5
,r
an
ge
:
8Æ
5–
27
Æ2
A
ll
p
at
ie
n
ts
w
er
e
o
n
gl
u
co
co
rt
ic
o
id
re
p
la
ce
m
en
t
at
su
p
ra
p
h
ys
io
lo
gi
ca
ld
o
se
s
24
-h
A
B
P
M
SB
P
:1
15
Æ1
±
10
Æ3
D
B
P
:6
8Æ
3
±
7Æ
2
R
o
ch
e
et
al
.4
3
C
la
ss
ic
21
-O
H
d
efi
ci
en
cy
(3
8)
•
Sa
lt
-w
as
ti
n
g
(3
8)
23
$;
15
#
11
Æ2
,r
an
ge
:
6Æ
1–
18
Æ2
A
ll
p
at
ie
n
ts
re
ce
iv
ed
re
p
la
ce
m
en
t
th
er
ap
y
in
th
e
fo
rm
o
f
o
ra
lh
yd
ro
co
rt
is
o
n
e
an
d
fl
u
d
ro
co
rt
is
o
n
e
24
-h
A
B
P
M
M
ea
n
24
-h
B
P
:
SB
P
:1
24
Æ9
±
11
Æ7
D
B
P
:7
6Æ
2
±
14
Æ9
V
o¨
lk
le
t
al
.4
4
C
la
ss
ic
21
-O
H
-d
efi
ci
en
cy
(5
5)
•
Sa
lt
-w
as
ti
n
g
(4
5)
•
Si
m
p
le
vi
ri
li
zi
n
g
(1
0)
32
$;
23
#
5Æ
3–
19
Æ0
(r
an
ge
)
A
ll
p
at
ie
n
ts
re
ce
iv
ed
re
p
la
ce
m
en
t
th
er
ap
y
w
it
h
gl
u
co
co
rt
ic
o
id
s:
h
yd
ro
co
rt
is
o
n
e
(4
0)
,
p
re
d
n
is
o
n
e
(1
2)
o
r
d
ex
am
et
h
as
o
n
e
(3
)
53
p
at
ie
n
ts
re
ce
iv
ed
fl
u
d
ro
co
rt
is
o
n
e
24
-h
A
B
P
M
24
-h
B
P
in
SD
S
fo
r
ag
e:
#
:S
B
P
0Æ
23
#
:D
B
P
-0
Æ6
5
$:
SB
P
0Æ
47
$:
D
B
P
-0
Æ6
5
H
o
ep
ff
n
er
et
al
.4
5
C
la
ss
ic
21
-O
H
d
efi
ci
en
cy
(3
4)
•
Sa
lt
-w
as
ti
n
g
(2
8)
•
Si
m
p
le
vi
ri
li
zi
n
g
(6
)
21
$;
13
#
6–
17
ye
ar
s
(n
=
23
)
18
–
26
ye
ar
s
(n
=
11
)
A
ll
p
at
ie
n
ts
re
ce
iv
ed
gl
u
co
co
rt
ic
o
id
tr
ea
tm
en
t
w
it
h
h
yd
ro
co
rt
is
o
n
e
In
o
u
tp
at
ie
n
t
cl
in
ic
:
o
sc
il
lo
m
et
ri
c
d
ev
ic
e
(n
=
34
),
u
n
d
er
h
o
sp
it
al
iz
at
io
n
:2
4-
h
B
P
m
ea
su
re
m
en
t
w
it
h
p
o
rt
ab
le
o
sc
il
lo
m
et
ri
c
d
ev
ic
e
(n
=
34
)
an
d
24
-h
A
B
P
M
(n
=
11
)
B
P
va
lu
es
in
11
ch
il
d
re
n
an
d
ad
o
le
sc
en
ts
w
h
o
p
ar
ti
ci
p
at
ed
in
al
lt
h
re
e
m
ea
su
re
m
en
ts
:
D
ay
-m
ea
n
SB
P
in
h
o
sp
it
al
:1
25
Æ9
±
9Æ
6
D
ay
-m
ea
n
D
B
P
in
h
o
sp
it
al
:7
8Æ
5
±
7Æ
0
SB
P
in
o
u
tp
at
ie
n
t
cl
in
ic
:1
17
Æ1
±
11
Æ8
D
B
P
in
o
u
tp
at
ie
n
t
cl
in
ic
:7
2Æ
6
±
6Æ
3
D
ay
-m
ea
n
SB
P
o
f
A
B
P
M
:1
14
Æ8
±
5Æ
7
D
ay
-m
ea
n
D
B
P
o
f
A
B
P
M
:6
8Æ
7
±
4Æ
6
N
eb
es
io
et
al
.4
6
C
la
ss
ic
21
-O
H
d
efi
ci
en
cy
(9
1)
49
$;
42
#
U
n
kn
o
w
n
A
ll
p
at
ie
n
ts
w
it
h
h
yp
er
te
n
si
o
n
w
er
e
tr
ea
te
d
w
it
h
b
o
th
h
yd
ro
co
rt
is
o
n
e
an
d
fl
u
d
ro
co
rt
is
o
n
e
(n
=
5)
R
et
ro
sp
ec
ti
ve
ch
ar
t
re
vi
ew
,m
et
h
o
d
s
o
f
B
P
m
ea
su
re
m
en
t
u
n
kn
o
w
n
P
ea
k
re
co
rd
ed
SB
P
fo
r
ea
ch
p
at
ie
n
t
w
it
h
h
yp
er
te
n
si
o
n
(n
=
4)
:1
15
/1
46
/3
00
/1
46
R
ef
,r
ef
er
en
ce
;S
D
,s
ta
n
d
ar
d
d
ev
ia
ti
o
n
;O
H
,h
yd
ro
xy
la
se
;B
P
,b
lo
o
d
p
re
ss
u
re
;S
B
P
,s
ys
to
li
c
b
lo
o
d
p
re
ss
u
re
;D
B
P
,d
ia
st
o
li
c
b
lo
o
d
p
re
ss
u
re
;A
B
P
M
,a
m
b
u
la
to
ry
b
lo
o
d
p
re
ss
u
re
m
o
n
it
o
ri
n
g.
Cardiovascular risk in congenital adrenal hyperplasia 141
 2010 Blackwell Publishing Ltd, Clinical Endocrinology, 73, 137–146
daytime and nocturnal hypertension, six patients (54%) had noc-
turnal hypertension and eight patients (73%) had nocturnal blood
pressures above the 90th percentile.
Roche et al.43 performed 24-h ambulatory blood pressure moni-
toring in 38 salt-wasting 21-hydroxylase-deficient patients (15
males, 23 females) with a mean age of 11Æ2 years. Using task force
references for office blood pressure measurements47 instead of
24-h ambulatory specific references, which would have been more
appropriate, they found that 58% of the patients had systolic
hypertension and 24% had diastolic hypertension. Mean daytime
systolic blood pressure was significantly higher than in the refer-
ence population and 84% had no physiological nocturnal systolic
dip. Mean systolic and diastolic blood pressures were not signifi-
cantly different between males and females. In CAH patients, there
was a positive relationship between systolic blood pressure and
BMI, which was most marked in females.
Vo¨lkl et al.44 performed 24-h ambulatory blood pressure moni-
toring in 55 treated patients with proven 21-hydroxylase deficiency
(32 females, 23 males) aged between 5 and 19 years. Measured
blood pressure values were transformed into SDS matched for age,
height, sex and the same oscillometric method respectively. Their
data showed a significantly elevated systolic blood pressure during
both day- and night-time (daytime 0Æ67 SDS, nighttime 0Æ63 SDS).
Surprisingly, diastolic blood pressure was significantly decreased
during the day with normal values during the night. A normal noc-
turnal drop of systolic blood pressure was found. Blood pressure
parameters positively correlated with BMI and skinfold thickness.
Hoepffner et al.45 focused on differences in blood pressure mea-
sured in the outpatient clinic and in the ward in 23 children and
adolescents and 11 adult CAH patients. All patients received gluco-
corticoid treatment with hydrocortisone. Blood pressure measured
during hospital admission was significantly elevated in children
and adolescents compared with that measured in the outpatient
clinic. All blood pressures measured were within the normal range.
Measurement of 24-h ambulatory blood pressure showed blood
pressure values in the normal range in all patients. No correlations
were found between blood pressure on one hand, and sex, BMI or
dosage of mineralocorticoids on the other hand.
Nebesio et al.46 performed a retrospective chart review of chil-
dren with 21-hydroxylase deficiency to evaluate the prevalence of
hypertension, defined as blood pressure >95th percentile for age
and gender, using published reference values. Six of 91 patients
showed hypertension (6Æ6%). Patients were aged 58 days –
12Æ6 years at the time of hypertension diagnosis. No relation
between blood pressure and BMI or dosage of hydrocortisone was
found. Nebesio et al.46 concluded that children with 21-hydroxy-
lase deficiency have a higher prevalence of hypertension compared
with historical reports on hypertension in a paediatric population.
In conclusion, in most studies performed in young CAH
patients, there is a tendency towards an increased prevalence of
hypertension. Further studies are required to investigate this rela-
tion in older CAH patients. It is well known that mineralocorticoid
excess, like in primary aldosteronism or in forms of CAH with ele-
vated levels of adrenal steroids with mineralocorticoid effect such
as 11-hydroxylase deficiency, results in high blood pressure.48
Therefore, treatment with too high doses of mineralocorticoids or
unjustified treatment with mineralocorticoids in patients with the
SV type of CAH with suppressed renin levels may cause high blood
pressure. However, in the reviewed papers, no correlations between
renin levels and blood pressure values were observed in CAH
patients.42–46 Glucocorticoid excess, as in Cushing’s syndrome, is
also known to result in high blood pressure.49 Therefore, treatment
with relatively high doses of glucocorticoids may also play a role in
the development of high blood pressure in CAH patients.50
Insulin resistance
Nine studies have investigated insulin sensitivity in CAH patients,
as summarized in Table 3.11,17,27,36–39,51–53 Most studies have used
the homeostasis model assessment method (HOMA-IR) or the oral
glucose tolerance test (OGTT) to assess insulin sensitivity. Only the
study of Paula et al.51 has applied the forearm model combined
with local indirect calorimetry, and showed that insulin sensitivity
was decreased in adult females with CAH, compared with female
controls. Thirty minutes after glucose ingestion, the serum insulin
levels in their group of patients were significantly higher than in
healthy controls. In a study by Speiser et al.,52 using OGTT, insulin
sensitivity was significantly lower than expected for BMI in patients
compared with controls (4Æ1 ± 0Æ6 vs. 9Æ7 ± 1Æ2 [min/lU/ml];
P < 0Æ05). Saygili et al.37 measured insulin sensitivity by HOMA-
IR in untreated nonclassic 21-hydroxylase-deficient adult women,
and found insulin resistance and hyperinsulinaemia. HOMA-IR
was 3Æ2 ± 0Æ8 in patients and 1Æ8 ± 0Æ6 in controls. Serum fasting
and nonfasting insulin levels in patients were significantly higher
than in controls (14Æ6 ± 10Æ3 vs. 4Æ2 ± 0Æ5 IU/l, P < 0Æ001 and
85Æ4 ± 20Æ5 vs. 30Æ2 ± 3Æ5 IU/l, P < 0Æ001, respectively). Insulin
resistance and hyperinsulinaemia were associated with hyperan-
drogenism. Serum leptin levels did not differ between patients and
controls.
Sartorato et al.39 studied insulin sensitivity in 19 adult patients
with CAH caused by 21-hydroxylase deficiency, using OGTT and
HOMA-IR. Significantly elevated fasting plasma insulin levels
(11Æ6 ± 3Æ20 lU/ml vs. 5Æ18 ± 2Æ4 lU/ml, P < 0Æ0001) and
HOMA-IR (2Æ46 ± 1Æ9 vs. 1Æ12 ± 0Æ58, P = 0Æ0033) were found in
CAH patients compared with controls.
An OGTT was also performed in adult CAH patients by Bachelot
et al.11 HOMA-IR was used to calculate insulin sensitivity. No con-
trol subjects were used in this study. During OGTT, two of 45
CAH-patients were identified with glucose intolerance. HOMA-IR
was calculated in 40 patients: 1Æ58 ± 0Æ26 in salt wasting patients,
2Æ01 ± 0Æ91 in simple virilizing patients and 1Æ39 ± 0Æ19 in patients
with the nonclassical form of CAH. HOMA-IR was significantly
correlated with BMI and 17-OHP levels. Bachelot et al.11 con-
cluded, based on HOMA-IR, that insulin sensitivity tends to
decrease when BMI and androgen levels increase.
In contrast to the studies discussed earlier, Bayraktar et al.,38
using HOMA-IR, did not find a decrease in insulin sensitivity in
CAH patients. HOMA-IR was 2Æ18 ± 0Æ11 for CAH patients and
2Æ16 ± 0Æ09 in controls. In addition, Buffington et al.53 found no
insulin resistance in CAH patients. Fasting and glucose-challenged
insulin levels, glucose disappearance rates after insulin injection
and in vitro insulin binding were similar to lean controls. However,
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the inclusion of both nonclassic 21-hydroxylase-deficient patients
and 3b-hydroxysteroid dehydrogenase-deficient patients results in
difficulty to arrive at solid conclusions. Furthermore, no data were
provided about the age of the participating patients and controls.
Two studies have evaluated insulin sensitivity in paediatric CAH
patients.17,36 Charmandari et al.36 found that HOMA-IR was sig-
nificantly elevated in children with classic CAH, compared to
healthy children (2Æ2 ± 0Æ3 vs. 0Æ7 ± 0Æ04, P < 0Æ001). CAH
patients had significantly higher fasting serum insulin concentra-
tions and significantly lower serum adrenaline and metanephrine
levels. Vo¨lkl et al.17 measured HOMA-IR in 51 patients, aged 5Æ1–
19Æ6 years, with CAH caused by 21-hydroxylase deficiency. No
control subjects were investigated. A HOMA-IR of 2Æ7 was found
and the authors concluded that CAH patients were characterized
by insulin resistance.
In summary, nine studies have explored insulin sensitivity either
in adult or in paediatric CAH patients. Different methods were
used to assess insulin sensitivity. Most studies suggest that CAH
patients tend to develop insulin resistance, but studies using the
gold standard technique to measure insulin sensitivity (eugly-
acemic hyperinsulinaemic clamp method) are lacking. In female
CAH patients, hyperandrogenism may induce insulin resistance. In
males, hypogonadism is associated with insulin resistance. Most
studies assessing insulin sensitivity in CAH patients contained only
female patients.37,38,51–53 Studies evaluating insulin sensitivity in a
selected population with male CAH patients are lacking and a pos-
sible association between hypogonadism and insulin sensitivity has
not been studied. No differences in insulin sensitivity between
males and females were discussed in the studies containing both
male and female CAH patients.11,17,36,39 Unfortunately, glucocor-
ticoids used to treat hyperandrogenism also induce insulin resis-
tance.3 Therefore, both treated and untreated CAH patients seem
to be at risk to develop insulin resistance. In children, reference
data are lacking for most parameters used to diagnose insulin resis-
tance. Therefore, it is difficult to diagnose insulin resistance in chil-
dren and predict future disease risk.54
Intima-media thickness
An increased intima-media thickness (IMT) has been described
as a surrogate marker of atherosclerosis and consequently a
higher cardiovascular risk.55,56 Sartorato et al.39 used the echo-
Doppler method for evaluation of IMT of the abdominal aorta,
right and left common carotid arteries, carotid bulbs and com-
mon femoral arteries in adult CAH patients, all treated with
glucocorticoids (aged 28 ± 3Æ5 years, n = 19). Significantly
increased values for IMT in all arteries were found compared
with healthy controls. No correlation was found between IMT on
the one hand and fasting glucose, insulin levels, cumulative doses
of glucocorticoids, 17-OHP or androstenedione levels on the
other hand. As increased IMT is an independent predictor of vas-
cular events, Sartorato et al.39 concluded that CAH patients
might be at risk of developing coronary, cerebrovascular and
peripheral vascular disease.
Conclusion
We have reviewed the current evidence regarding the presence of
conventional cardiovascular risk factors, more specifically obesity,
insulin resistance, high blood pressure and elevated lipid concen-
trations in CAH patients. Overall, these studies demonstrate the
existence of an increased fat mass, insulin resistance and an
elevated blood pressure but a normal lipid profile in CAH patients.
Taken together, these findings suggest that adult CAH patients
seem to have a high risk to cluster a number of risk factors, fitting
within the metabolic syndrome. The finding of an increased IMT
in these patients suggests that these risk factors may indeed trans-
late to cardiovascular disease.
It has been suggested that CAH patients develop an unfavourable
cardiovascular risk profile either because the existence of hyperan-
drogenism in untreated or undertreated patients or because of the
(supra)physiological doses of glucocorticoids used to suppress
androgen levels to normal values (graphically shown in Fig. 1).
Many other metabolic abnormalities, such as an altered leptin axis,
may contribute to the development of cardiovascular disease.
Further studies providing comprehensive information regarding
cardiovascular risk profile are warranted, especially in older
patients. Whether these risks are of a magnitude that justifies
pharmacological intervention and at what age this should be
started are further issues that need to be solved.
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Fig. 1 Hypothetical curves, showing the relation between androgen levels
and glucocorticoid dosages in CAH patients. Untreated CAH patients have
high androgen levels. Supraphysiological doses of glucocorticoids are
needed to normalize androgen levels. Interindividual differences in
glucocorticoid sensitivity (shown by the different curves), caused by
different mechanisms,57–59 may explain differences in glucocorticoid dosage
between individual patients. Patients with impaired glucocorticoid
sensitivity need higher glucocorticoid dosage to suppress androgen levels
and these patients might have a higher chance to develop an unfavourable
cardiovascular risk.
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